Loading…
Incidence of Neonatal Abstinence Syndrome - 28 States, 1999-2013
Neonatal abstinence syndrome (NAS) is a postnatal drug withdrawal syndrome that occurs primarily among opioid-exposed infants shortly after birth, often manifested by central nervous system irritability, autonomic over-reactivity, and gastrointestinal tract dysfunction. During 2000-2012, the inciden...
Saved in:
Published in: | MMWR. Morbidity and Mortality Weekly Report 2016, Vol.65 (31), p.799 |
---|---|
Main Authors: | , , , , , |
Format: | Report |
Language: | English |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Neonatal abstinence syndrome (NAS) is a postnatal drug withdrawal syndrome that occurs primarily among opioid-exposed infants shortly after birth, often manifested by central nervous system irritability, autonomic over-reactivity, and gastrointestinal tract dysfunction. During 2000-2012, the incidence of NAS in the US significantly increased. Several recent publications have provided national estimates of NAS; however, data describing incidence at the state level are limited. CDC examined state trends in NAS incidence using all-payer, hospital inpatient delivery discharges compiled in the State Inpatient Databases of the Healthcare Cost and Utilization Project (HCUP) during 1999-2013. Primary prevention measures are important in curbing the incidence of NAS. In 2016, CDC released the Guideline for Prescribing Opioids for Chronic Pain, which recommends that clinicians consider nonopioid pharmacologic therapy for chronic pain management, discuss family planning and how long-term opioid use might affect future pregnancies before initiating opioid therapy in reproductive-aged women, and prescribe the lowest effective dose when opioids are started. |
---|---|
ISSN: | 0149-2195 1545-861X |